Indian drug makers need to shift focus to complex therapies than mere launches: Jefferies

Mumbai: Indian pharma companies, who have built their revenues by selling generic drugs to developed markets, might have to shift their business strategy as an overcrowded US market and peaking opportunities threaten to bring down revenues from the developed markets , says research firm Jefferies.

"With opportunities peaking and competition rising in the developed markets, we believe emerging markets (EM) will drive future growth. We prefer companies with high exposure to chronic/complex therapies and strong EM presence", according to the research report from Jefferies.

The report suggests that Indian drug companies have to shift their focus to limited competition therapies, where portfolios, brand and quality matter more than mere launches.